Literature DB >> 8935808

Behavioral effects of sertindole, risperidone, clozapine and haloperidol in Cebus monkeys.

D E Casey1.   

Abstract

Extrapyramidal side effects (EPS) are major limitations to neuroleptic treatment of psychoses. To evaluate further the behavioral characteristics of the novel antipsychotic agents, a wide range of single intramuscular doses of sertindole (0.1-2.5 mg/kg IM), risperidone (0.01-0.25 mg/kg IM), clozapine (1.0-25.0 mg/kg IM), and haloperidol (0.01-0.25 mg/kg IM) were blindly evaluated at weekly intervals in Cebus monkeys previously sensitized to neuroleptics. All drugs except clozapine produced dystonia and parkinsonian symptoms, but haloperidol and risperidone were 50-100 times more potent than sertindole in producing EPS. Sertindole, risperidone and haloperidol had no significant sedative effects, whereas clozapine produced dose related sedation. Risperidone, clozapine and haloperidol but not sertindole decreased locomotor activity. Sertindole, risperidone and clozapine had a calming effect at doses below the EPS threshold, unlike haloperidol. Sertindole has many behavioral effects in nonhuman primates that are similar to those seen with the new antipsychotics, risperidone and clozapine, which suggests a favorable antipsychotic benefit/risk ratio in the clinic, especially regarding EPS.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8935808     DOI: 10.1007/bf02245613

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  21 in total

1.  Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects.

Authors:  L Peacock; T Solgaard; H Lublin; J Gerlach
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  The effects of clozapine on tardive dyskinesia.

Authors:  J A Lieberman; B L Saltz; C A Johns; S Pollack; M Borenstein; J Kane
Journal:  Br J Psychiatry       Date:  1991-04       Impact factor: 9.319

3.  Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values.

Authors:  H Y Meltzer; S Matsubara; J C Lee
Journal:  J Pharmacol Exp Ther       Date:  1989-10       Impact factor: 4.030

4.  Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain.

Authors:  A Fink-Jensen; P Kristensen
Journal:  Neurosci Lett       Date:  1994-11-21       Impact factor: 3.046

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Serotonergic aspects of acute extrapyramidal syndromes in nonhuman primates.

Authors:  D E Casey
Journal:  Psychopharmacol Bull       Date:  1989

7.  Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.

Authors:  J Peuskens
Journal:  Br J Psychiatry       Date:  1995-06       Impact factor: 9.319

8.  The acute effect of sertindole on brain 5-HT2, D2 and alpha 1 receptors (ex vivo radioreceptor binding studies).

Authors:  J Hyttel; J B Nielsen; G Nowak
Journal:  J Neural Transm Gen Sect       Date:  1992

9.  Noncataleptogenic, centrally acting dopamine D-2 and serotonin 5-HT2 antagonists within a series of 3-substituted 1-(4-fluorophenyl)-1H-indoles.

Authors:  J Perregaard; J Arnt; K P Bøgesø; J Hyttel; C Sánchez
Journal:  J Med Chem       Date:  1992-03-20       Impact factor: 7.446

10.  Neuroleptic-induced acute dyskinesias in squirrel monkeys: correlation with propensity to cause extrapyramidal side effects.

Authors:  J Liebman; R Neale
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  7 in total

Review 1.  Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients.

Authors:  Richard J Beninger; Tyson W Baker; Matthew M Florczynski; Tomek J Banasikowski
Journal:  Neurotox Res       Date:  2010-04-08       Impact factor: 3.911

2.  A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia.

Authors:  D P van Kammen; J P McEvoy; S D Targum; D Kardatzke; T B Sebree
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  Assessment of adverse effects of neurotropic drugs in monkeys with the "drug effects on the nervous system" (DENS) scale.

Authors:  Subramaniam Uthayathas; Christopher L Shaffer; Frank S Menniti; Christopher J Schmidt; Stella M Papa
Journal:  J Neurosci Methods       Date:  2013-02-16       Impact factor: 2.390

Review 4.  How do the atypical antipsychotics work?

Authors:  J Ananth; K S Burgoyne; R Gadasalli; S Aquino
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 5.  Sertindole : a review of its use in schizophrenia.

Authors:  David Murdoch; Gillian M Keating
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Treatments for chronic psychosis.

Authors:  C A Tamminga; A C Lahti
Journal:  Dialogues Clin Neurosci       Date:  2001-12       Impact factor: 5.986

7.  Brain findings associated with risperidone in rhesus monkeys: magnetic resonance imaging and pathology perspectives.

Authors:  Guillermo Fernandez; Sabu Kuruvilla; Catherine D G Hines; Frédéric Poignant; James Marr; Thomas Forest; Richard Briscoe
Journal:  J Toxicol Pathol       Date:  2019-05-13       Impact factor: 1.628

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.